

Section of Hematology and Medical Oncology Newsletter



In This Issue:

Awards/Promotions: 2-3
Publications/Presentations: 4-5
HemOnc Faculty & Staff Award Winners: 6
HemOnc Survivor Celebration: 7
Annual Faculty Review Sign Up: 8
Call for Applications: 9
2025 Service Award Recipients: 10
BU APP Council Seeks New Members: 11
BU Profile Q & A Session: 12
New Observership Submission Form: 13
Faculty & Staff Recognition Award: 14
Upcoming Events/Social Media: 15



Welcome to **Tresha R. Parsania, MBBS, MPH**, who has joined the Section of Hematology and Medical Oncology as a Clinical Research Coordinator II. Tresha will support clinical and translational research activities within the Translational Research Laboratory and Biospecimen Repository. Tresha earned her Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from India and recently completed her Master of Public Health (MPH) in Epidemiology and Biostatistics at Boston University. Prior to joining the section, she gained clinical experience in medical oncology and has been involved in both clinical and translational research.




HemOnc Awards/Promotions



Margaux Dockerty-Martin

Margaux Dockerty-Martin MSN, AGNP-C has been promoted to Assistant Professor of Medicine at Boston University Chobanian & Avedisian School of Medicine, effective May 21, 2026.

This promotion recognizes Margaux's outstanding contributions to our Section of Hematology & Medical Oncology and her continued commitment to excellence in patient care, leadership, education, and service. We are fortunate to have her as a member of our team and grateful for the expertise, dedication, and compassion she brings to our patients and colleagues every day.



Nicole McQuade

Nicole McQuade MS, PA-C has been promoted to Assistant Professor of Medicine at Boston University Chobanian & Avedisian School of Medicine, effective May 21, 2026.

This promotion recognizes Nicole's many contributions to our Section of Hematology & Medical Oncology and her ongoing commitment to exceptional patient care, education, and service. We are grateful for the expertise, professionalism, and dedication she brings to our patients, colleagues, and trainees each day.



Nebby Stephen

Nebby Stephen, NP was recently nominated for the DAISY Nurse Award, a recognition program that honors nurses who provide extraordinary compassionate care and make a meaningful difference in the lives of patients and families.

Being nominated is a significant achievement and reflects the positive impact Nebby has on our patients, colleagues, and community every day.

Please join us in congratulating Nebby on this well-deserved recognition and thanking her for her dedication to exceptional patient care.

HemOnc Awards/Promotions



Tashia Prince-Lacombe

Tashia Prince-Lacombe, DNP, NP-C, Chief APP for Hematology & Oncology, has been named a 2026 Be Exceptional Award Winner at Boston Medical Center!

This is an extraordinary honor. More than 200 nominations were submitted across the institution, and Tashia was selected as one of only 12 individual recipients recognized for exemplifying BMC's mission, values, and commitment to exceptional patient care.

This recognition is a testament to Tashia's outstanding leadership, dedication to our patients, and unwavering commitment to supporting our APPs, faculty, staff, and trainees. Since stepping into her role as Chief APP, Tashia has continued to strengthen our clinical programs, champion professional development, and foster a culture of collaboration, compassion, and excellence throughout our section.

Those of us who have the privilege of working with Tashia know that this award reflects what she demonstrates every day: a deep commitment to our patients and colleagues, a willingness to go above and beyond, and a genuine passion for improving the care we provide to our community. Please join me in congratulating Tashia on this well-deserved recognition. We are incredibly fortunate to have her as a leader within our section and are proud to celebrate this achievement with her.

Congratulations, Tashia!

Publications/Presentations



Martin Steinberg, PhD

Drs. Jason Lofters, Andrew Wilks, and Elizabeth Klings, with Dr. Martin Steinberg posted a preprint on medRxiv describing the use of HbF/F-cell as a biomarker in sickle cell disease.

Dr. Steinberg was a member of a team that published in the NEJM the use of gene therapy with exa-cel in children with sickle cell disease and thalassemia.

Frangoul H, de la Fuente J, Chopra Y, Meisel R, Amrolia PJ, Algeri M, Sharma A, Cappellini MD, Corbacioglu S, Kattamis A, Lobitz S, de Montalembert M, Rondelli D, Sheth S, Steinberg MH, Walters MC, Boerner K, Liu T, Zairis S, Hobbs W, Grupp SA, Locatelli F; CLIMB THAL-141 and CLIMB SCD-151 Study Groups. Exa-cel in children with transfusion-dependent β -thalassemia or sickle cell disease. N Engl J Med. 2026. doi:10.1056/NEJMoa2603387.

Additionally, Dr. Steinberg was visiting Professor at Hopital Henri Mondor, Paris France from June 5-9, 2026, where he presented a lecture, "Fetal Hemoglobin in Sickle Cell Anemia."



Kim Vanuytsel, PhD

Congratulations to Dr. Kim Vanuytsel on being featured in HealthCity for her research focused on expanding access to transformative gene therapies for individuals with sickle cell disease. The feature highlights the collaborative work between basic scientists and clinicians across our Section and the Center of Excellence for Sickle Cell Disease, translating discoveries from the laboratory to patient care. The article also showcases Dr. Vanuytsel's innovative iPSC platform, which serves as a preclinical drug screening tool designed to incorporate genetic diversity and support the development of more effective therapies.

Additionally, Dr. Kim Vanuytsel and colleagues on the release of a new preprint describing an innovative induced pluripotent stem cell (iPSC) platform for sickle cell disease. While the manuscript has not yet undergone peer review, it highlights the collaborative work taking place across our Section to expand treatment options for patients with sickle cell disease. The platform serves as a preclinical drug screening tool that incorporates genetic diversity, helping researchers evaluate potential therapies and advance more personalized approaches to care.

Publications



Vaishali Sanchorawala, MD

Congratulations to [Dr. Vaishali Sanchorawala](#) and collaborators on four recent publications advancing the understanding and treatment of amyloidosis. These studies explore improved diagnostic approaches for AL amyloidosis, evaluate patient-reported quality of life in ATTR amyloidosis, refine prognostic models in the era of daratumumab-based therapy, and describe a rare dual-clone phenomenon involving concurrent AL amyloidosis and B-cell lymphoproliferative disorders.

1) George T, Staron A, Burks EJ, Szalat RE, Sanchorawala V. Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis. *Br J Haematol*. 2026 Mar 29. doi: 10.1111/bjh.70461. Epub ahead of print. PMID: 41905782.

2) Sanchorawala V, Greatsinger A, Staron A, Berk JL, Mendelson LM, Joshi T, J Burke N, Tabatabaeepour N, Smith J, Signorovitch J. Disease burden of ATTR amyloidosis based on the SF-36® health survey. *Cardiooncology*. 2026 Apr 15;12(1):51. doi: 10.1186/s40959-026-00482-2. PMID: 41987333; PMCID: PMC13085746.

3) Berumen A, Staron A, Kalaitzidis G, Siddiqi OK, Gopal DM, Ruberg FL, Sanchorawala V. Evaluating AL-ISS within a BNP-Based Model for AL Amyloidosis in the Daratumumab Era. *Blood Adv*. 2026 Apr 17;bloodadvances.2026020177. doi: 10.1182/bloodadvances.2026020177. Epub ahead of print. PMID: 41995749.

4) Cetin O, Staron A, Mendelson L, Joshi T, Sanchorawala V. Rare dual-clone phenomenon: concurrent λ AL amyloidosis and κ -restricted Bcell lymphoproliferative disorders. *Haematologica*. 2026 Apr 9. doi: 10.3324/haematol.2026.300678. Epub ahead of print. PMID: 41952623.




Umit Tapan, MD

[Dr. Umit Tapan](#) and collaborators on their recent [publication](#) advancing the treatment of lung cancer. The study highlights emerging therapeutic strategies and clinical evidence aimed at improving outcomes for patients with thoracic malignancies, reflecting the Section's continued commitment to translating cutting-edge research into better patient care.

Hill NR, Crosbie A, Szymialis R, Botros A, Zhang Y, Tapan U. [Impact of social determinants of health on treatment patterns and outcomes in metastatic non-small cell lung cancer](#). *J Oncol Pharm Pract*. Published online May 20, 2026. doi:10.1177/10781552261449764.

HemOnc Faculty & Staff Award Winners

HEMATOLOGY & MEDICAL ONCOLOGY *Faculty & Staff Recognition Award Winners*



*Gareth Morgan, PhD
Faculty Award Winner*



*Janet Allieu
Staff Award Winner*

HemOnc Survivor Celebration



19th Annual
Cancer Survivors Celebration

If you have ever experienced cancer, you are a cancer survivor!
This is a day of celebration for you and your loved ones.
Come enjoy lunch, music, photos, prizes, games, and more!

**Saturday, June 27, 2026
10:30 a.m.-1:00 p.m.**

**Boston Medical Center
Shapiro Center Lobby**
725 Albany Street, Boston, MA 02118

MAKE YOUR RESERVATION

Call 617-638-7540 or 617-414-5726,
OR email SupportPrograms@bmc.org,
OR scan the QR code!



FREE PARKING in the 710 Albany Street Garage



Support Programs
for Cancer and for
Sickle Cell Disorders

Annual Faculty Review Sign Up

This is a friendly reminder to sign up for your Annual Faculty Review with Dr. Gignac if you have not already done so. We encourage everyone to select a meeting time, particularly over the next few weeks, so that we can ensure all reviews are completed before the August 31, 2026 deadline.

Faculty Annual Review Sign-Up Sheet:

<https://docs.google.com/spreadsheets/d/1SzzArVDuE8bbjk1doUkOdjzHltIODB4pJJCrhU-U6sM/edit?usp=sharing>

For those who have already signed up, thank you! Calendar invitations have been sent for all scheduled review meetings.

As a reminder, please complete the faculty review form prior to your meeting at:

<https://www.bumc.bu.edu/facdev>

If you experience any issues with scheduling, your calendar invitation, or the Faculty Development system, please feel free to reach out

Call for Applications: Evans Medical Foundation Board of Directors

Dear Colleagues,

I am writing to seek applications for faculty to serve on the Evans Medical Foundation Board of Directors. The Board meets annually to evaluate performance of the Department of Medicine and to recommend strategic initiatives. Board service is generally for a one-year term, renewable for up to four consecutive years of service and Board members must be members of the Faculty Practice Plan (BUMG) . We are seeking diverse faculty participation in the hopes of harnessing the best ideas for our future. If you are interested in serving on the EMF Board, please forward a statement of interest to Jen Fitzgerald at jennifer.fitzgerald@bmc.org.

Thank you for your consideration!

Vicki Jackson MD, MPH
John Wade Professor
Chair of Medicine
Boston University Chobanian & Avedisian School of Medicine
Physician-in-Chief and Chief, Department of Medicine
Boston Medical Center
72 East Concord Street, Evans 113
Boston, Massachusetts 02118-2526
T 617 358-3510 F 617 358-3509

2025 Service Award Recipients

Please join me in congratulating our Section of Hematology & Oncology faculty and staff who will be recognized as part of the 2025 BMC Service Awards program for reaching important service milestones. We are grateful for their dedication, contributions, and commitment to our patients, colleagues, trainees, and institution.

2025 Service Award Honorees

25 Years of Service

- Martin Steinberg, MD

10 Years of Service

- Charlene Sylvestre, NP
- Peter Everett, MD

5 Years of Service

- Hussein Assi, MD
- Nebulla (Nebby) Stephen, NP
- Tashia Prince-Lacombe, NP

BU APP Council Seeks New Members

The APP Council is seeking new APP members for FY27, effective October 1, 2026. Seats are open to BMC or BUMG-employed APPs. We encourage all interested APPs to consider applying.

BUMG and BMC value all faculty and embrace diversity at all levels of the organization. We are committed to building and sustaining an equitable and inclusive community that values diversity of gender, race/ethnicity, and academic rank in all departments, sections, and committees/councils. We know diverse committee/council membership is essential to deliver on our mission and, at BUMG and BMCHS, our diverse experiences, skills, and backgrounds advance our thinking and innovation.

Committee/Council

Purpose

Meeting Days/Times

Committee Chair

APP Council

Promote, develop and support the roles of APPs

12:00PM-1:00PM, third Thursday of the month

Ludwine Paul

The minimum time commitment for APP Council membership is one (1) hour each month for meetings. Members may serve no more than two (2) consecutive three-year (3) terms.

To apply to the APP Council, please [click here](#) to submit a brief statement of interest (200 words or less) and your current CV by Thursday, July 2nd, 2026.

If you have any questions, please contact [Michael Halas](#).

Thank you!

John Wood

Chief of Staff

BUMG Office of Administration

[Click to Apply](#)

BU Profile Q & A Session

June 25 - BU Profiles Drop-in Q&A Session (Virtual)

Just drop in anytime during the session with your BU Profiles questions!

- How do grants and publications get onto my BU profile, and can I edit them?
- How do I use BU Profiles to find collaborators?
- Can you add this great new feature I thought of?
- I don't have a BU profile. How do I get one?

BU Profiles allows you to network and collaborate with colleagues, find potential mentors, search for relevant panel members and advisory board expertise, evaluate research trends by investigator, and broadly survey the community at large while displaying your academic credentials, publications, research and related career information to that same community.

Join the session at the Zoom link below:

Web Site: [https://bostonu.zoom.us/j/99100702002?](https://bostonu.zoom.us/j/99100702002?pwd=TTFOMmszcm9acGZMRkhjQVM0VjZlZz09)

[pwd=TTFOMmszcm9acGZMRkhjQVM0VjZlZz09](https://bostonu.zoom.us/j/99100702002?pwd=TTFOMmszcm9acGZMRkhjQVM0VjZlZz09)

Contact: Jim Vlachos | jvlachos@bu.edu | (617) 358-1988

Date: Thursday, June 25 | Noon-1 p.m.

Location: Zoom

New Observership Submission Form

We would like to remind you all of the launch of our new online submission form for Observership applications that is now located on our website. This new system is designed to streamline the application process and make it smoother in the initial stages of onboarding.

Starting today, all observership applications must be submitted through the online form, which can be accessed at:

<https://www.bumc.bu.edu/hematology/observership-requests/>. The form also includes the rules and regulations, which were discussed at our last Section meeting, that were put in place by BMC.

If you have already submitted an application through email, there is no need to reapply using the new form. However, you are encouraged to use the online system for any future applications.

Faculty & Staff Recognition Award

Call for Nominations!



Do you know someone who has gone above and beyond? Nominate them today and let their efforts be celebrated!


<https://www.bumc.bu.edu/hematology/faculty-staff-awards/>

The section of Hematology & Medical Oncology “Employee Recognition Award” is designed to recognize faculty and staff who work within administration, clinical care and research. This award serves as a means to celebrate excellence, foster a culture of appreciation, and inspire continuous improvement within the departmental community. It is designated for those who have demonstrated outstanding contributions, deliver exceptional service, and go above and beyond their expected duties in the section and the Cancer Center.

Upcoming Events

Follow Us on Instagram!

Hematology & Medical Oncology is LIVE on Instagram!
Follow us at [@BMCHemOnc](https://www.instagram.com/BMCHemOnc)



If you or one of your patients would like to be featured,
please submit a request at
<https://www.bumc.bu.edu/hematology/announcement-requests/>

Available Career Opportunities as of June 2026:

- Clinical Investigator, Gastrointestinal Oncology
- Clinical Investigator, Genitourinary Oncology
- Advanced Practice Provider, Neuro-Oncology and CNS Malignancies
- Director, Ambulatory Medical Director
- Director, Neuro-Oncology Program
- Director, Sickle Cell Program
- Clinical Investigator Hematology/Hematologic Malignancies
- Advanced Practice Provider, Stem Cell Program
- Advanced Practice Provider, Hematology and Hematologic Malignancies
- Advanced Practice Provider: Sickle Cell Disease and Hemoglobinopathies
- Physician: Academic Clinical Investigator- Breast Oncology